Cervarix, GSK's cervical cancer vaccine, approved in Korea

Published: 2008-07-25 06:54:00

Updated: 2008-07-25 06:54:00

GlaxoSmithKline (GSK) says that the Korea Food and Drug Administration has granted a marketing authorization for its cervical cancer vaccine, Cervarix.

Cervarix, with its innovative AS04 adjuvant system, is indicated for the prevention of precancerous cervical lesions and cervical cancer caus...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK